Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of VX-993
NCT06508762Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VX-993 in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 28, Area Under the Concentration Versus Time Curve for the Last Measurable Concentration at Day 28 and 1 more. Started Jul 2024; status: completed.
02
Drugs
VX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06508762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508762.